Skip to main content
. 2024 Oct 17;28(3):672–683. doi: 10.1038/s41391-024-00906-z

Fig. 1. Considerations during treatment selection for patients with mCRPC*.

Fig. 1

CT computed tomography, mCRPC metastatic castration-resistant prostate cancer, PET positron emission tomography, PSMA prostate-specific membrane antigen. *Please note that not all factors presented in this figure were within the scope of this review.